Similar Efficacy for Intranasal, Intramuscular Naloxone

Share this content:
Similar Efficacy for Intranasal, Intramuscular Naloxone
Similar Efficacy for Intranasal, Intramuscular Naloxone

TUESDAY, Nov. 28, 2017 (HealthDay News) -- For reversal of opioid overdose, higher-concentration intranasal naloxone has similar efficacy to that of intramuscular naloxone administered at the same dose, according to a review published online Nov. 27 in the Annals of Internal Medicine.

Roger Chou, M.D., from the Oregon Health & Science University in Portland, and colleagues conducted a systematic review to synthesize evidence on the effects of naloxone route of administration and dosing for suspected overdose in out-of-hospital settings, and the need for transport to a health care facility after reversal of overdose with naloxone. Data were included from 13 eligible studies.

The researchers found that one trial demonstrated similar efficacy between higher-concentration intranasal naloxone and intramuscular naloxone administered at the same dose (2 mg/mL). One trial found that lower-concentration intranasal naloxone was less effective than intramuscular naloxone, but the risk for agitation was reduced (low strength of evidence). There was insufficient evidence to assess other comparisons for administration route. Low rates of death and serious adverse events were reported in six uncontrolled studies in non-transported patients after successful naloxone treatment.

"Higher-concentration intranasal naloxone (2 mg/mL) seems to have efficacy similar to that of intramuscular naloxone for reversal of opioid overdose, with no difference in adverse events," the authors write. "Non-transport after reversal of overdose with naloxone seems to be associated with a low rate of serious harms, but no study evaluated risks of transport versus non-transport."

Abstract/Full Text
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease



Sign up for myCME e-newsletters




More in Home

FDA Approves First Generic Under-the-Tongue Suboxone

FDA Approves First Generic Under-the-Tongue Suboxone

May only be prescribed by Drug Addiction Treatment Act-certified prescribers

Kellogg's Honey Smacks Cereal Recalled Due to Salmonella Risk

Kellogg's Honey Smacks Cereal Recalled Due to <i>Salmonella</i> ...

Twenty-four people have been hospitalized, but no deaths have been reported

Portable Music Player Use Linked to Hearing Loss in Children

Portable Music Player Use Linked to Hearing Loss ...

Increased odds of high-frequency hearing loss with portable music player use

is free, fast, and customized just for you!




Already a member?

Sign In Now »